Galmed Pharma (GLMD) Tops Q2 EPS by 4c

Galmed Pharma (NASDAQ: GLMD) reported Q2 EPS of ($0.21), $0.04 better than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition
• Ennis (EBF) Reports In-Line Q1 EPS